{"id":46287,"date":"2025-10-20T18:49:10","date_gmt":"2025-10-20T16:49:10","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/targeting-sall4-with-an-hla-class-i-restricted-tcr-for-cancer-immunotherapy\/"},"modified":"2025-10-20T18:49:10","modified_gmt":"2025-10-20T16:49:10","slug":"targeting-sall4-with-an-hla-class-i-restricted-tcr-for-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/targeting-sall4-with-an-hla-class-i-restricted-tcr-for-cancer-immunotherapy\/","title":{"rendered":"Targeting SALL4 with an HLA Class I-restricted TCR for cancer immunotherapy"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Oct 20. doi: 10.1158\/2326-6066.CIR-24-0207. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Aberrant expression of the oncogene SALL4 is associated with stemness, more aggressive cancer phenotype, and reduced patient survival in various tumor types making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer (CRC) tissues and demonstrated that SALL4 was overexpressed in primary tumor and paired liver metastasis. Then, we identified the SALL4-derived S9V peptide as a naturally processed peptide that induced specific CD8+ T-cell responses from the peripheral blood of gastrointestinal cancer patients whereas no responses were observed for the peripheral blood of healthy donors. Thereafter, we isolated a SALL4-specific T-cell receptor (TCR) that recognized this peptide in the most common HLA molecule in the Caucasian population, HLA-A2, and used this to develop TCR-engineered T cells. In vitro analysis showed that SALL4 TCR-redirected primary CD8+ T cells exhibited cytotoxic effects against SALL4-expressing tumor cells and produced effector cytokines. In vivo, SALL4-TCR T cells significantly reduced tumor growth and improved survival of tumor-bearing mice. Moreover, SALL4-TCR T cells displayed no toxicity against hematopoietic stem cells. Thus, we conclude that T cells engineered to express a SALL4-specific TCR have the potential to be effective as immunotherapy for solid cancers and pave the way for further clinical development.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41114529\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20251020124908&amp;v=2.18.0.post9+e462414\">41114529<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0207\">10.1158\/2326-6066.CIR-24-0207<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Oct 20. doi: 10.1158\/2326-6066.CIR-24-0207. Online ahead of print. ABSTRACT Aberrant expression of the oncogene SALL4 is associated with stemness, more aggressive cancer phenotype, and reduced patient survival in various tumor types making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer (CRC) &#8230; <a title=\"Targeting SALL4 with an HLA Class I-restricted TCR for cancer immunotherapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/targeting-sall4-with-an-hla-class-i-restricted-tcr-for-cancer-immunotherapy\/\" aria-label=\"Read more about Targeting SALL4 with an HLA Class I-restricted TCR for cancer immunotherapy\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-46287","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/46287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=46287"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/46287\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=46287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=46287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=46287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}